[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glp-1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glp-1":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,46,79,113,138,165,194,214,236,262,280,309,334],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639891","impact-of-glp-1-receptor-agonists-on-dry-eye-disease-in-patients-with-type-2-diabetes-mellitus-and-obesity-100639891",false,"NCT07605572","Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity","GALENOS","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Patients who have not previously received GLP-1 receptor agonists (GLP-1 RAs).\n3. Patients able to provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding patients.\n2. History of multiple severe hypoglycemic episodes within the past two years.\n3. Active intraocular inflammation in either eye, such as infectious conjunctivitis, keratitis, scleritis, endophthalmitis, or autoimmune uveitis.\n4. Patients who have undergone cataract surgery or vitrectomy within the past 6 months.\n5. History of ketoacidosis or metabolic acidosis.\n6. History of corneal transplantation.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Diabetes mellitus (DM), prediabetes, and obesity are emerging as major global public health problems, with their epidemic spread continuously increasing over the past decades. The occurrence of diabetic retinopathy, cataract, glaucoma, and ocular surface disease in patients with diabetes mellitus has been extensively investigated in several studies. However, mild ocular surface disorders, such as dry eye disease, have often been overlooked, with a previous study showing that 51.3% of diabetes-related dry eye disease cases remained underdiagnosed. Among systemic diseases, diabetes mellitus and obesity have been associated with an increased risk of developing dry eye disease. Chronic hyperglycemia in diabetes leads to microvascular damage, including corneal neuropathy and reduced tear production, conditions that can disrupt ocular surface health, while systemic inflammation and meibomian gland dysfunction also contribute to this process. However, the effect of newer classes of antidiabetic medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), on ocular surface health remains insufficiently understood. The aim of this prospective cohort study is to evaluate the effects of GLP-1 receptor agonists on dry eye disease in patients with type 2 diabetes mellitus and obesity through the assessment of ocular surface parameters, such as tear film break-up time, Schirmer test results, as well as potential changes in corneal topography.",[24,25,26,27,28,29],"Dry Eye Disease (DED)","Diabete Mellitus","GLP-1","Ocular Surface","Diabetes Type 2","Cornea",[31,28,32,29],"Dry eye disease","GLP-1 Receptor Agonists","RECRUITING","2026-05-29",{"date":36,"type":37},"2026-06-02","ACTUAL",{"date":39,"type":37},"2026-03-01",{"date":41,"type":20},"2027-02-28",{"name":43,"class":44},"Attikon Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100636963","slowly-digestible-carbohydrates-for-glp-1-secretion-100636963","NCT07572513","Slowly Digestible Carbohydrates for GLP-1 Secretion","Inclusion Criteria:\n\n1. Healthy population\n2. BMI between 18.5 and 24.9 kg\u002Fm2\n3. Adults 18 - 45 years old\n4. Men or women\n5. Able to read\u002Fspeak English\n6. Fasting blood glucose levels ≤100 mg\u002FdL\n7. HbA1c ≤ 5.7%\n\nExclusion Criteria:\n\n1. Participants with 18 \\> Years of Age \\> 45 will be excluded.\n2. Subjects with 18.5 kg\u002Fm² \\> BMI \\> 24.9 kg\u002Fm² will be excluded.\n3. Diabetic individuals will be excluded.\n4. Individuals with history of gastrointestinal disease will be excluded from the study.\n5. Pregnant or nursing women will also be excluded.\n6. Individuals taking GLP-1 medications, or on weight-loss diets or restrictive eating patterns.\n7. Individuals suffering from dairy or gluten intolerance or allergies will be excluded.",true,"45 Years",{"count":55,"type":20},19,"INTERVENTIONAL",[58],"NA","The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss.\n\nResearchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 60, 120, 180 minutes and after a second meal.\n\nThere will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will:\n\n* Consume a randomized test beverage (SDC or maltodextrin)\n* Receive a blood draw at 7 timepoints over 3 hrs\n* Take a satiety questionnaire 5 times over 3 hrs\n* Consume a standardized lunch 3 hrs after the test beverage consumption",[61,26,62,63,64],"Blood Glucose","Satiety","Second Meal Intake","Healthy Participant Study",[26,66,67,68,62,69,70,61],"Slowly-Digestible Starch","Ileal-Digesting Starch","Dietary Starch","Starch","raw corn starch","2026-05-01",{"date":73,"type":37},"2026-05-07",{"date":71,"type":20},{"date":76,"type":20},"2026-11-25",{"name":78,"class":44},"Purdue University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":45},"100613918","impact-of-semaglutide-ozempicwegovy-on-heart-and-muscle-mass-100613918","NCT07272837","Impact of Semaglutide (Ozempic\u002FWegovy®) on Heart and Muscle Mass","GLP-1 Receptor Agonist-Induced Loss and Impairment of Muscle Mass - Evaluation of Response","GLIMMER","Inclusion Criteria:\n\n* Adults 18-80 years of age\n* Starting semaglutide for type 2 diabetes or weight loss\n* Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)\n\nExclusion Criteria:\n\n* Current use of semaglutide for more than 2 weeks\n* Major recent heart issues or other severe health conditions\n* Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)\n* Dependence on a mobility aid (unable to participate in exercise MRI)","80 Years",{"count":89,"type":20},50,"The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.\n\nThis study involves (3) in-person study visits. At each visit, participants will be asked to:\n\n* Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.\n* Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.\n* Complete questionnaires related to demographics, health information, physical activity, and nutrition.\n* Have a blood sample collected from a vein in your arm.\n* Have your blood levels assessed through three finger pricks.\n* Complete three days of food records.",[92,93,94,26,95],"Type 2 Diabetes","Obesity","Semaglutide","Diabetes",[94,92,95,93,97,98,99,100,101,26,102,103],"Body Composition","Muscle Mass","Skeletal Muscle Mass","Cardiac Muscle Mass","GLP-1 Receptor Agonist","MRI","Magnetic Resonance Imaging","2026-04-15",{"date":106,"type":37},"2026-04-20",{"date":108,"type":20},"2026-04-14",{"date":110,"type":20},"2028-04-30",{"name":112,"class":44},"University of Alberta",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":56,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100626613","a-randomized-triple-blind-placebo-controlled-study-to-evaluate-the-effects-of-a-supplement-on-nutrient-gaps-and-gut-health-among-individuals-utilizing-glp-1-ras-100626613","NCT07437911","A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs","Inclusion Criteria:\n\n* Be male or female\n* Be aged 18-59.\n* Has a BMI between 20-31.9.\n* Anyone currently taking GLP-1 medication at their maintenance dose (week 8+), and without any plans to alter their dosage. This includes: Semaglutide (Ozempic®, Wegovy®, Rybelsus®), Liraglutide (Saxenda®, Victoza®), Dulaglutide (Trulicity®), Exenatide (Byetta®, Bydureon®), Lixisenatide (Adlyxin®)\n* Anyone willing to follow the study protocol, including immediately prior to the all blood tests, duplicating their diet for 72 hours (3 days), refraining from caffeine and exercise for 24 hours, and fasting for 10 hours.\n* Anyone willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.\n* Anyone willing to avoid introducing any other supplements, medications, or herbal remedies for the duration of this trial.\n* Anyone who is generally healthy - does not live with any diagnosed uncontrolled chronic disease.\n* Has access to a consistent weighing scale for the duration of the study.\n* Resides in the United States.\n\nExclusion Criteria:\n\n* Anyone with a diagnosis of Type I or Type II diabetes.\n* Anyone with a diagnosis of any metabolic health condition, such as hypertension and dyslipidemia.\n* Anyone who has taken any multivitamin\u002Fmultimineral supplements within the past 3 months.\n* Anyone who has taken a probiotic supplement within the past month.\n* Anyone who has regularly consumed (5 days\u002Fweek or more) products that target healthy aging, anti-aging, longevity, gut health, energy, or ingestive behaviour (such as cravings), including resveratrol, quercetin, pterostilbene, coQ10, grapefruit, nicotinamide riboside, prebiotic fiber, green tea, niacin (vitamin B3) within the past 2 months.\n* Anyone who has received an antibiotic, antifungal, antiparasitic, or antiviral treatment within the past 90 days.\n* Anyone who has a known history of severe digestive disorders or metabolic conditions that impact nutrient absorption or metabolism, including acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, a history of colon resection, gastroparesis, Inborn errors of metabolism (such as PKU), or gastrointestinal tract surgeries.\n* Anyone with any known allergies or hypersensitivities to any supplement product ingredients.\n* Anyone with any chronic health conditions that could impact participation in this study, such as asthma, gout, fibromyalgia, chronic inflammatory conditions (such as Crohn's, Lupus, HIV\u002FAIDS), thyroid conditions, cancer (within the past 5 years), mental health disorders, history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period.\n* Anyone currently pregnant, trying to conceive, or breastfeeding.\n* Anyone who has undergone a change in hormone therapy (including oral contraceptives) within the past 4 weeks, or is unwilling to maintain their current hormone therapy\u002Foral contraceptive use throughout the course of the study.\n* Anyone who consumes more than 2 standard alcoholic drinks per day or more than 10 drinks per week, or has within the past 6 months.\n* Anyone who is currently a smoker or has been a smoker within the past month.\n* Anyone who follows a specific exclusion diet, including vegan, vegetarian, carnivore, paleo, atkins, or ketogenic.","59 Years",{"count":121,"type":20},120,[58],"This study is a triple-blind, placebo-controlled, randomized controlled trial of 120 adults that will evaluate the impact of a novel nutritional supplement on improving nutrient gaps and changing nutrient status and the gut microbiome among glucagon-like peptide-1 receptor agonist (GLP-1 RA) users.",[125,126,127,26],"Nutrition Intake","Nutrition Status","Gastrointestinal Microbiome","2026-02-24",{"date":130,"type":37},"2026-02-27",{"date":132,"type":20},"2026-02",{"date":134,"type":20},"2026-08",{"name":136,"class":137},"Athletic Greens International","INDUSTRY",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":52,"sex":145,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":161,"leadSponsor":163,"locationsCount":45},"100625465","glp-1ra-effects-on-lean-mass-and-bone-health-in-midlife-women-100625465","NCT07422987","GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women","GLOW","Inclusion Criteria:\n\n* Females\n* Age 35-60 year\n* BMI≥30 or BMI≥27 and at least one cardiometabolic risk factor (dyslipidemia, hypertension, obstructive sleep apnea, metabolic syndrome, fatty liver, PCOS)\n* Newly prescribed a GLP-1RA medication\n* English speaking\n* Body weight stable for the past 6 months\n\nExclusion Criteria:\n\n* Pregnant women\n* Under age 35 or over age 60\n* Born male\n* Cannot consent for themselves\n* Cannot read and speak in English\n* Type 2 diabetes\n* Recently discontinued a GLP-1RA medication (less than 6-months since discontinuing)\n* Contraindications for taking a GLP-1 RA medication (personal or family history of medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2, personal history of pancreatitis, pregnancy, hypersensitivity to the drug or any component of the drug, active suicidal ideation)\n* Currently taking aromatase inhibitors or selective estrogen receptor modulators (SERMs)","FEMALE","35 Years","60 Years",{"count":89,"type":20},"This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.",[97,151,26,152],"Muscle Function","Estrogen Level",[154,155,156],"Midlife","Women's health","Dietary quality","2026-02-12",{"date":159,"type":37},"2026-02-20",{"date":157,"type":37},{"date":162,"type":20},"2027-06-30",{"name":164,"class":44},"University of Kansas Medical Center",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":56,"phases":174,"briefSummary":176,"conditions":177,"keywords":182,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100617123","phase-2-evaluating-the-impact-of-glp-1-receptor-agonists-with-total-neoadjuvant-therapy-in-rectal-cancer-100617123","NCT07314528","Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer","A Phase II Multi-institutional Randomized Trial Evaluating the Impact of GLP-1 Receptor Agonists in Combination With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n* Written informed consent according to local guidelines obtained prior to any study-related activities.\n* Histologically confirmed mismatch repair protein proficient adenocarcinoma of the rectum.\n* BMI ≥25 kg\u002Fm²\n* Radiological confirmed \\>T2, Node positive, Threatened Surgical Margin and\u002For EMVI+ by MRI\n* Imaging available for radiomics analysis\n* Absence of metastatic disease at registration.\n* Adequate renal function is defined as calculated creatinine clearance (CrCl) \\>50ml\u002Fmin.\n* ANC \\> 1.5 cells\u002Fmm3, HGB \\> 8.0 gm\u002Fdl, PLT \\> 150,000\u002Fmm3, total bilirubin ≤ 1.5 x ULN (except in patients with Gilbert's Syndrome who must have total bilirubin ≤ 3.0 x ULN), AST≤ 3 x ULN, ALT ≤ 3 x ULN\n* Able to tolerate medication.\n* ECOG 0-2\n\nExclusion Criteria:\n\n* Received prior chemotherapy or radiotherapy\n* Previous or concurrent active malignancy ≤ 5 years prior to registration, with the exception of non-melanotic skin cancer or carcinoma in situ of any type, or other cancers that the treating investigator does not feel will impact the study objectives.\n* Locally advanced disease T3N+ or T4 disease.\n* Recurrent rectal cancer\n* Metastatic disease at presentation\n* Patients unable to undergo MRI\n* Patients having already received weight-loss intervention (pharmacological or surgical)",{"count":173,"type":20},42,[175],"PHASE2","The goal of this clinical trial is to see if adding a weight loss medication (GLP-1 receptor drug) to patients with an increased BMI receiving treatment for rectal cancer prior to surgery (total neoadjuvant chemoradiotherapy) improves cancer outcomes. The main questions it aims to answer is\n\n1. Does the drug increase weight loss in rectal cancer patients with a high BMI\n2. Does the drug improve response rates to chemotherapy and radiotherapy\n3. Does the drug improve survival outcomes and if cancer returns\n\nResearchers will compare this drug in one group against a group of patients receiving preoperative total neoadjuvant chemoradiotherapy without the drug\n\nPatients will be required to\n\n1\\) take the GLP-1 receptor agonist drug during TNT or just having TNT alone as per standard hospital protocols\n\nBody weight will be measured at three predefined time points:\n\n1. Baseline: Prior to initiation of semaglutide or TNT\n2. Pre-TNT: Start of TNT (for the intervention arm, this is 4 weeks after semaglutide initiation)\n3. Post-TNT: Within 7 days following completion of TNT and prior to definitive surgery\n\nPatients will complete their treatment and go on to have surgery as per standard methods for treating rectal cancer",[178,179,180,181,26],"Rectal Cancer Patients","Obesity &Amp; Overweight","Locally Advanced Rectal Cancer (LARC)","Total Neoadjuvant Therapy",[183,181,101],"Locally Advanced Rectal Cancer","NOT_YET_RECRUITING","2025-12-17",{"date":187,"type":37},"2026-01-02",{"date":189,"type":20},"2026-04",{"date":191,"type":20},"2028-09",{"name":193,"class":44},"St. James's Hospital, Ireland",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":45},"100613738","the-effect-of-pharmacotherapy-with-glp-1-and-gipglp-1-analogs-on-changes-in-qualitative-and-quantitative-parameters-of-the-diet-as-well-as-metabolic-and-behavioral-parameters-in-patients-with-excess-body-weight-100613738","NCT07270497","The Effect of Pharmacotherapy With GLP-1 and GIP\u002FGLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight","Inclusion Criteria:\n\n* Age 18-65 years,\n* Diagnosed obesity (BMI ≥ 30 kg\u002Fm²) or overweight (BMI ≥ 27 kg\u002Fm²) with comorbidities associated with excess body weight (including type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease),\n* Eligibility for treatment with GLP-1 or GIP\u002FGLP-1 analogues,\n* Not taking GLP-1 and GIP\u002FGLP-1 analogue medications for at least one year prior to study enrollment,\n* Ability to provide informed consent,\n* Informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Age under 18 or over 65 years,\n* Inability to qualify for treatment with GLP-1 and GIP\u002FGLP-1 analogues,\n* Pregnancy or breastfeeding,\n* Diagnosed eating disorders,\n* Active cancer or gastrointestinal conditions that may affect the absorption or tolerance of treatment (e.g., inflammatory bowel disease, conditions after extensive gastrointestinal resections, conditions after bariatric surgery),\n* Inability to participate in regular follow-up visits,\n* Inability to provide informed consent,\n* Failure to provide informed consent to participate in the study.","65 Years",{"count":19,"type":20},"The aim of this study is to comprehensively assess the early and long-term effects of GLP-1 and GIP\u002FGLP-1 analogue medications on metabolic and behavioral parameters, with particular emphasis on qualitative and quantitative dietary changes in patients undergoing treatment for overweight and obesity. Participation in the study will involve four follow-up visits per year at the Clinic of Diabetology and Internal Medicine, Central Clinical Hospital, University Clinical Clinical Hospital, Medical University of Warsaw: before treatment initiation and after 3, 6, and 12 months. The analysis will focus not only on metabolic effects (weight loss, changes in body composition, and improved biochemical parameters), but also on nutritional and behavioral aspects, including diet, appetite regulation, risk of malnutrition and muscle loss, and the occurrence of adverse events. The study will allow for a multifaceted assessment of the impact of treatment with GLP-1 and GIP\u002FGLP-1 analogues on patients with excess body weight.",[26,204],"Nutrition","2025-11-25",{"date":207,"type":37},"2025-12-08",{"date":209,"type":37},"2025-08-15",{"date":211,"type":20},"2026-08-14",{"name":213,"class":44},"Medical University of Warsaw",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":56,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100609014","impact-of-probiotic-ultraflora-triplebiotic-on-weight-evolution-on-people-after-discontinuation-of-glp-1-treatment-100609014","NCT07209046","Impact of Probiotic (UltraFlora® Triplebiotic) on Weight Evolution on People After Discontinuation of GLP-1 Treatment.","A Randomized, Double-blind, Double-arm Study Conducted Directly With Consumers Via an App \"Baritastic App\", Evaluating the Efficacy of a Supplement Containing Bifidobacterium Lactis B420 and Pasteurized Akkermansia Muciniphila (UltraFlora® Triplebiotic) for 3 Months in Adults After Discontinuation of GLP-1 Treatment.","Inclusion Criteria:\n\n1. Providing written informed consent\n2. Males and females of at least 18 years old\n3. Body mass index (BMI) between 25 and 30 (including 25 and 30) (Weight: 25 \\\u003C BMI \\\u003C 30)\n4. Having undergone treatment with GLP-1 for more than 3 months but for less than 1 year.\n5. Having stopped GLP-1 treatment for a maximum of 4 weeks\n6. Being willing to maintain stable dietary habits and physical activity levels throughout the trial period\n7. Being willing not to introduce any other food supplements during the trial period (supplements used in the two weeks prior to enrolling in the trial and used consistently throughout are acceptable, except for probiotics).\n\nExclusion Criteria:\n\n1. Being on GLP-1 treatment\n2. Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation.\n3. Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and\u002For being immunocompromised.\n4. Suffering from any uncontrolled endocrine disorder.\n5. Having consumed any probiotic supplements in the 3 months prior to enrollment.\n6. Having used any antibiotic treatment in the 3 months prior to enrollment.\n7. Having a known allergy to the ingredients in the study product.\n8. Being pregnant or lactating (breastfeeding) or trying to become pregnant.\n9. Participating in an other clinical trial.\n10. Suffering from dementia or inability to take the trial treatment in an appropriate way.\n11. Taking UltraFlora® Triplebiotic or any similar product from competitors prior to trial participation",{"count":222,"type":20},128,[58],"This is a randomized, double-blind, double arm study involving 128 participants who will undergo a total participation period of 12 weeks.",[226,26],"Adults","2025-09-29",{"date":229,"type":37},"2025-10-06",{"date":231,"type":20},"2025-11-01",{"date":233,"type":20},"2026-07-31",{"name":235,"class":137},"Metagenics, Inc.",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":200,"enrollmentInfo":244,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":45},"100596224","behavioral-therapy-and-glp-1-analogue-effects-on-binge-eating-weight-and-coping-in-obesity-100596224","NCT07042672","Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity","Behavioral Therapy With and Without GLP-1 Analogue in Patients With Morbid Obesity and Binge Eating Disorder: A Clinical Prospective Observational Study on Body Weight, Binge Eating Behavior, and Harmful Coping Strategies","BETTER-GLP1","Inclusion criteria\n\n1. Severe obesity defined as BMI \\>40 kg\u002Fm2 or 35 kg\u002Fm2 with obesity-related comorbidities: coronary artery disease, heart failure, hypertension, atrial fibrillation, cerebral stroke, venous thromboembolism, obstructive sleep apnea, obesity hypoventilation syndrome, type 2 diabetes mellitus, non-alcoholic fatty liver disease, dyslipidemia, osteoarthritis and polecystic ovary syndrome\n2. Age between 18 to 65 years\n3. Diagnosis of BED according to DSM-5 criteria\n4. Willingness to participate and provide informed consent\n5. Able to understand and communicate in Norwegian\n\nExclusion criteria\n\n1. Pregnant or lactating women, as well as women planning pregnancy within one year.\n2. Current use medications with major effects on appetite regulation or weight (including, but not limited to systemic glucocorticoids and antipsychotic medication)\n3. Renal failure with estimated glomerular filtration rate less than 30 mL\u002Fmin\u002F1,73m2\n4. Liver failure with either ASAT and\u002For ALAT 5 times upper reference limit, or ALP and\u002For GT more than 3 times upper reference limit, or clinical signs of liver decompensation\n5. Active cancer\n6. Previous medullary thyroid cancer\n7. Previous pancreatitis\n8. Active substance abuse (but previous drug abuse accepted)\n9. Medical or psychological treatment within the specialized health care service for eating disorders within the last 6 months.\n10. Ongoing severe psychiatric disease that makes them unable to follow the lifestyle treatment program\n11. Any illness or prior treatment that in the opinion of the investigator would jeopardize the patient's participation in the study or impact integrity and\u002For quality of study data.\n12. Previous bariatric surgery\n13. Use of appetite suppressing drugs (e.g., GLP-1 analogues and\u002For naltrexone\u002Fbupropion) within the last 6 months\n14. Participation in another clinical study involving an investigational medicinal product within 1 month prior to study inclusion",{"count":245,"type":20},80,"This study is a clinical, longitudinal, non-randomized, prospective observational study that seeks to compare the treatment effects and safety of using GLP-1 analogues versus not using appetite suppressants during a lifestyle treatment program that includes individual consultations every fourth month and 10 weeks of CBT-E group therapy in patients with both obesity and BED.\n\nThe primary objective of this study is to evaluate the impact on BED symptomatology, while the secondary objectives include examining the potential adoption of alternative harmful coping mechanisms. Additionally, the study will assess psychological well-being and weight changes and their consequent influence on obesity-associated comorbid conditions.\n\nAdult patients with coexisting obesity and BED presenting at the Obesity clinic at Haukeland University Hospital, Bergen, Norway, will be included Patients will be divided into two groups: Group-GLP1 (n = 40), who will use GLP-1 analogues, and Group-NoMED (n = 40), who will not use appetite suppressants. Both groups will otherwise follow the routine standardized patient care pathway with follow-up controls every four months and participation in CBT group therapy sessions.\n\nChanges in symptoms of BED, alternative harmful coping strategies and mental health will be recorded at baseline and 12 months using patient-reported questionnaires, as well as anthropometric and biochemical data.",[248,249,250,251,26,252,179],"Binge Eating Disorder Associated With Obesity","Binge Eating Disorder","Eating Disorder Binge","Eating Disorders","CBT","2025-09-09",{"date":255,"type":37},"2025-09-15",{"date":257,"type":37},"2025-07-01",{"date":259,"type":20},"2028-12-31",{"name":261,"class":44},"Haukeland University Hospital",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":56,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":277,"leadSponsor":279,"locationsCount":4},"100602967","impact-of-multivitamin-phytomulti-and-a-probiotic-ultraflora-balance-probiotic-on-gut-health-of-people-taking-glp-1-medication-100602967","NCT07130396","Impact of Multivitamin (PhytoMulti®) and a Probiotic (UltraFlora® Balance Probiotic) on Gut Health of People Taking GLP-1 Medication","A Single Arm Trial to Evaluate the Effect of PhytoMulti® Multivitamin and UltraFlora® Balance Probiotic on Bowel Symptoms in Individuals Using GLP-1 Receptor Agonists, Assessed by the IBS Symptom Severity Score (IBS-SSS)","Inclusion Criteria:\n\n1. Providing written informed consent\n2. Males and females of at least 18 years old\n3. Minimum 4 weeks on GLP-1 (f.e Ozempic®, Wegovy®, Mounjaro®, etc.) and maximum 1 year on GLP-1\n4. Body Mass Index (BMI) ≥ 25 AND ≤ 30\n5. Being willing to maintain stable dietary habits and physical activity levels throughout the trial period\n6. Being willing not to introduce any other food supplements during the trial period (supplements used in the two weeks prior to enrolling in the trial and used consistently throughout are acceptable, except for probiotics).\n\nExclusion Criteria:\n\n1. Having had any type of bariatric surgery, or planned bariatric surgery during the period of trial participation.\n2. Suffering from a severe chronic disease (e.g., cancer, HIV, hepatic or renal impairment, diabetes type I), inflammatory bowel disease (IBD), Coeliac Disease, and\u002For being immunocompromised.\n3. Suffering from any uncontrolled endocrine disorder\n4. Having used any antibiotic treatment in the 2 months prior to enrollment.\n5. Having a known allergy to the ingredients in the study product.\n6. Being pregnant or lactating (breastfeeding) or trying to become pregnant.\n7. Participating in another clinical trial.\n8. Suffering from dementia or inability to take the trial treatment in an appropriate way.\n9. Taking PhytoMulti® Multivitamin and\u002For UltraFlora® Probiotic or any similar product from competitors prior to trial participation",{"count":19,"type":20},[58],"This is a single-arm, open-label clinical trial involving 100 participants who will undergo a total participation period of 12 weeks.",[26,226],"2025-08-12",{"date":275,"type":37},"2025-08-19",{"date":231,"type":20},{"date":278,"type":20},"2026-04-30",{"name":235,"class":137},{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":56,"phases":291,"briefSummary":293,"conditions":294,"keywords":298,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":45},"100600063","phase-2-effectiveness-of-alternative-therapies-in-maintaining-weight-loss-achieved-by-glp-1-medications-post-cessation-100600063","NCT07092618","Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation","Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation: A Randomized, Controlled Trial","Inclusion Criteria:\n\n* Existing AgelessRx patient\n* Adults (40 - 85 years of age)\n* Any sex\n* Any ethnicity\n* BMI ≥ 22 kg\u002Fm\\^2\n* Have been on GLP-1s (Wegovy, Ozempic, or a compounded form of GLP-1s) for at least three months before study initiation\n* Have lost at least 15 lbs during their GLP-1 use\n\nExclusion Criteria:\n\n* Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)\n* History of bariatric surgery\n* Use of weight-loss medications other than GLP-1s within the past 6 months\n* Age \\\u003C40 years\n* Contraindications to naltrexone, metformin, or rapamycin\n* Significant psychiatric illness that may affect participation\n* Pregnant or breastfeeding individuals","40 Years","85 Years",{"count":290,"type":20},150,[175,292],"PHASE3","The goal of this randomized, controlled trial is to evaluate the effectiveness of alternative therapies (metformin alone, with rapamycin, and with low-dose naltrexone) in maintaining weight loss in patients weaning off GLP-1 medications.\n\nThe main questions it aims to answer are:\n\n* Whether the combination of metformin, with or without rapamycin or low-dose naltrexone, will be adequate to maintain the relative weight of individuals gradually discontinuing GLP-1 receptor agonist use.\n* Whether individuals discontinuing GLP-1 receptor agonist use who instead use a combination of metformin, with or without rapamycin or low-dose naltrexone, will experience less weight regain over the course of six months post-cessation than those who do not use any alternative medications.\n\nResearchers will compare the four groups: 1) control, 2) metformin, 3) metformin + rapamycin, and 4) metformin + low-dose naltrexone, to assess changes in the percentage of weight regain, metabolic indicators (e.g., HbA1c, lipid profile), and quality of life PROs, six months after cessation of GLP-1 therapy.\n\nParticipants will:\n\n* Administer the assigned intervention following a dosing and administration protocol provided by the study and medical team.\n* Complete a medical intake for overall health status, medical history and demographic information,\n* Complete patient-reported outcomes\u002Fsurveys and assessments\n* Complete blood work at baseline and every 16 weeks thereafter to measure CBC, CMP, and standard health biomarker panels (e.g., cholesterol, glucose, creatinine, sodium, potassium).\n* Share data from health wearables with the research team throughout the study to improve the accuracy of evaluating activity, sleep, heart rate, and other related healthspan measures.",[295,26,296,297],"Longevity","Geroscience","Aging",[295,297,299,26],"Healthy Aging","2025-07-28",{"date":302,"type":37},"2025-07-30",{"date":304,"type":37},"2024-12-17",{"date":306,"type":20},"2025-08",{"name":308,"class":137},"AgelessRx",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":184,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":45},"100594074","impact-of-glp-1-receptor-agonists-on-patients-with-ipmn-100594074","NCT07014709","Impact of GLP-1 Receptor Agonists on Patients With IPMN","Impact of GLP-1 Receptor Agonists on Patients With Intraductal Papillary Mucinous Neoplasms: A Retrospective Multicentric Cohort Study","IPMN-GLP1RA","Inclusion Criteria:\n\n* \\> 18 years old\n* Radiological diagnosis of IPMN\n* Treated with GLP-1 RAs.\n* Patients must have provided prior informed consent for the use of their coded clinical data in research.\n\nExclusion Criteria:\n\n* radiological diagnosis of IPMN is unclear,\n* no documented history of GLP-1 RAs use\n* patients did not provide signed informed consent, or have documented refusal for research.",{"count":318,"type":20},30,"This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy. With the increasing use of GLP-1 RAs for managing diabetes and obesity, concerns about their potential to influence pancreatic conditions, like IPMNs, have emerged. Although GLP-1 RAs are generally safe, their effects on pre-existing pancreatic conditions remain unclear.\n\nThe study aims to evaluate whether GLP-1 RA use in IPMN patients is linked to changes in pancreatic cyst characteristics, the incidence of acute pancreatitis, variations in tumor markers, and the progression of IPMNs to high-grade dysplasia or malignancy. A retrospective analysis will be conducted using medical data from patients diagnosed with IPMNs and treated with GLP-1 RAs between 2010 and 2024 at three Swiss hospitals. Key outcomes will include radiological changes, the incidence of acute pancreatitis, and potential shifts in IPMN surveillance or need for surgical intervention",[321,322,26,323,324],"IPMN","IPMN, Pancreatic","Intraductal Papillary Mucinous Neoplasm of Pancreas","Glucagon-Like Peptide-1 Receptor Agonists","2025-06-02",{"date":327,"type":37},"2025-06-11",{"date":329,"type":20},"2025-05-31",{"date":331,"type":20},"2026-10-31",{"name":333,"class":44},"Hôpital Fribourgeois",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":342,"maxAge":200,"enrollmentInfo":343,"targetDuration":4,"studyType":56,"phases":345,"briefSummary":346,"conditions":347,"keywords":353,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":377},"100572518","maintain-mucosal-ablation-therapy-after-incretins-100572518","NCT06734312","MAINTAIN (Mucosal AblatIoN Therapy After INcretins)","Gastric Fundal Mucosal Ablation for Weight Management in Patients Stopping Glucagon-like Peptide-1 Receptor Agonists","MAINTAIN","Inclusion Criteria:\n\n1. Subjects aged 21-65\n2. Body mass Index (BMI) ≥30 kilograms per square meter (kg\u002Fm²), or ≤45 kg\u002Fm²\n3. Observed ≥ 10% TBWL with semaglutide or tirzepatide use for primary obesity therapy\n4. Subject did not experience \\>50% weight recurrence since discontinuation of semaglutide or tirzepatide\n5. Maintained a stable dose of semaglutide or tirzepatide for a minimum of 12 weeks\n6. Have recently discontinued or are planning to discontinue semaglutide or tirzepatide (≤ 24 weeks from last dose to time of study procedure)\n7. No previous medical history of diabetes mellitus\n8. Willing and able to participate in the study procedures\n9. Understand and voluntarily sign the informed consent\n\nExclusion Criteria:\n\n1. Known diagnosis of type I or type II diabetes or a Hemoglobin A1c \\> 6.5% at time of screening\n2. Use of GLP-1 or GLP-1\u002FGIP medication for the treatment of diabetes, rather than obesity.\n3. Use of anticoagulation, antithrombotic agents, and\u002For NSAIDs that cannot be discontinued for a minimum of 12 weeks\n4. Known bleeding diathesis that cannot be corrected through medical means.\n5. History of decompensated end-organ disease\n6. Unwillingness to abstain from the use of incretin mimetics during the study duration.\n7. Unwillingness to abstain from the use of tobacco during the study duration\n8. Patients on any medications or supplements including those that may influence cholecystokinin (CCK), glucose, growth hormone, insulin and\u002For somatostatin levels\n9. History of any stomach manipulation (including repair of hiatal hernia or fundoplication) deemed unsafe by PI for GFMA\n10. Active disordered eating\n11. Patients who do not give their consent to the enrollment in the study or are incompetent, unconscious or unable to express their consent for any reason\n12. Known diagnosis of gastroparesis or functional dyspepsia\n13. Patients who are pregnant, who plan to become pregnant during study duration, or patients of child-bearing potential who refuse effective birth control methods (as approved by PI)\n14. Active H. pylori infection or history of H pylori without treatment and confirmation of eradication\n15. Active gastric ulceration.\n16. Use of concomitant medications known to induce weight loss (including but not limited to liraglutide, phentermine, phentermine\u002Ftopiramate, bupropion\u002Fnaltrexone, metformin)","21 Years",{"count":344,"type":20},20,[58],"The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity. In this study, GFMA will be performed on patients who have experienced \\> 10% weight loss with GLP-1 therapy and who plan to discontinue use of GLP-1 medications for the duration of the study.",[348,349,350,351,26,352],"Obesity and Obesity-related Medical Conditions","Obesity and Overweight","Obesity Prevention","Obesity Recidivism","Ablation Techniques",[354,355,356,357,358,359,360,361,362,363,364,365,366,367],"obesity","obesity and overweight","endoscopic bariatric therapy","ablation","gastric mucosal ablation","GMA","GFMA","glp-1","weight loss medications","weight loss","semaglutide","tirzepatide","hunger","appetite","2025-03-18",{"date":370,"type":37},"2025-03-21",{"date":372,"type":37},"2025-01-01",{"date":374,"type":20},"2026-06",{"name":376,"class":44},"Dr. Christopher McGowan",2]